Juan Pablo Maya-Arteaga

Dr. Juan Pablo Maya-Arteaga

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Humberto Martínez OrozcoHumberto Martínez Orozco
Humberto Martínez Orozco
ABAlberto Bencomo-Martínez
Alberto Bencomo-Martínez
JMJuan Pablo Maya-Arteaga
Juan Pablo Maya-Arteaga
PAPedro Francisco Rubio de Anda
Pedro Francisco Rubio de Anda
FSFausto Sanabria
Fausto Sanabria
SDSofía Diaz-Cintra
Sofía Diaz-Cintra
The complexity of Alzheimer’s disease (AD) pathophysiology represents a significant challenge in the development of effective therapeutic agents for its treatment. CNEURO-201 (CN, also Amylovis-201) is a novel pharmaceutical agent with dual activity as an anti-amyloid-β (Aβ) agent and σ1 receptor agonist. CN exhibits great efficacy at very low doses, delaying cognitive impairment and alleviating Aβ load in animal models of AD. However, CN functions on other remains related to this pathology remain to be investigated. The present study sought to evaluate the effects of CN treatment at a dosage of 0.1 mg kg−1 (p.o) over an eight-week period in the 3xTg-AD mouse model. In silico studies, as well as biochemical and immunofluorescence assays, were conducted on brain tissue to investigate the CN effects on acetylcholine metabolism, redox system, and glial cell activation-related biomarkers in brain regions that are relevant for memory. The results demonstrated that CN effectively rescues cognitive impairment of 3xTg-AD mice by influencing glial activity to reduce existing Aβ plaques but also modulating acetylcholine metabolism and the enzymatic response of proteins involved in the redox system. Our outcomes reinforced the potential of CN in treating AD by acting on multiple pathways altered in this disease.

Verified
Journal Article
Open access
PDF file
NPNelly Jovana Pastén-Castrejón
Nelly Jovana Pastén-Castrejón
Humberto Martínez OrozcoHumberto Martínez Orozco
Humberto Martínez Orozco
GGGloria Yareli Gutiérrez-Silerio
Gloria Yareli Gutiérrez-Silerio
HHHebert Luis Hernández-Montiel
Hebert Luis Hernández-Montiel
JMJuan Pablo Maya-Arteaga
Juan Pablo Maya-Arteaga
SDSofía Diaz-Cintra
Sofía Diaz-Cintra
Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β (Aβ) and chronic neuroinflammation, with microglia playing a central role in its pathogenesis. Alterations in microglial metabolism have been proposed to contribute to AD-related inflammatory responses and reduced Aβ clearance, suggesting that thiamine-dependent pathways may be relevant in this context. Thiamine pyrophosphate (TPP), the active form of vitamin B1, is essential for glucose metabolism and mitochondrial function; however, its association with microglial changes in AD remains unclear. In this study, 9-month-old female triple-transgenic AD (3xTg-AD) mice and non-transgenic controls (NoTg) received TPP (2.0 mg/mL) or saline as a vehicle for six weeks via osmotic pumps. Nesting, a hippocampus-dependent behavioral test, as well analyses of Aβ burden, microglial morphology, and the expression of genes related to metabolic and immune pathways were evaluated. Differences in nesting behavior between experimental groups were observed, but TPP treatment was not associated with an evident change in 3xTg-AD mice. In the subiculum and CA1 regions of the hippocampus of female 3xTg-AD mice exposed to TPP, a lower Aβ burden was observed, and morphological variations in microglia were detected in both groups (3xTg-AD and NoTg). Additionally, in the brain of the TPP-treated group, some changes in mRNA gene expression were recorded. Together, these findings describe hippocampal microglial and amyloid profiles following TPP treatment in 3xTg-AD mice and provide a basis for further investigation of thiamine-dependent pathways in AD-related neuroinflammatory contexts.

18 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Humberto Martínez OrozcoHumberto Martínez Orozco
Humberto Martínez Orozco
ABAlberto Bencomo-Martínez
Alberto Bencomo-Martínez
JMJuan Pablo Maya-Arteaga
Juan Pablo Maya-Arteaga
PAPedro Francisco Rubio de Anda
Pedro Francisco Rubio de Anda
FSFausto Sanabria
Fausto Sanabria
SDSofía Diaz-Cintra
Sofía Diaz-Cintra
The complexity of Alzheimer’s disease (AD) pathophysiology represents a significant challenge in the development of effective therapeutic agents for its treatment. CNEURO-201 (CN, also Amylovis-201) is a novel pharmaceutical agent with dual activity as an anti-amyloid-β (Aβ) agent and σ1 receptor agonist. CN exhibits a great efficacy at very low doses, delaying cognitive impairment and alleviating Aβ load in animal models of AD. However, CN functions on other pathways related to this pathology remains to be investigated. The present study sought to evaluate the effects of CN treatment at a dosage of 0.1 mg kg-1 (p.o) over an eight-week period in the 3xTg-AD mouse model. In silico studies, as well as biochemical and immunofluorescence assays, were conducted on brain tissue to investigate the CN effects on acetylcholine metabolism, redox system and glial cell activation related biomarkers in brain regions that are relevant for memory. The results demonstrated that CN effectively rescues cognitive impairment of 3xTg-AD mice by influencing glial activity to reduce existing Aβ plaques, but also modulating acetylcholine metabolism and the enzymatic response of proteins involved in redox system. Our outcomes reinforced the potential of CN to treat AD by acting on multiple pathways altered in this disease.